Eculizumab in the treatment of neuromyelitis optica spectrum disorder

The article describes a clinical case of a 48-year-old female patient with AQP4-positive with attacks neuromyelitis optica spectrum disorder (NMOSD). The article presents an assessment of the dynamics of the neurological status, as well as the results of laboratory and instrumental examination. A literature review is provided on the epidemiological features and modern approaches to the treatment of NMOSD. In a patient with a NMOSD with attacks course resistant to standard immunosuppressive therapy (glucocorticosteroids, azathioprine), the administration of eculizumab led to stable clinical remission. No exacerbations were recorded over 18 months of observation. Eculizumab demonstrates high efficiency in preventing NMOSD attacks and reducing the degree of disability in patients with AQP4-IgG-positive NMOSD with attacks and early administration of targeted therapy is critically important for preventing cumulative neurological damage, improving the prognosis and quality of life of patients with NMOSD.